![](https://www.taivex.com/wp-content/uploads/2016/09/iStock-1186545957.jpg)
Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the US FDA to enter clinical development
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment